Current Report Filing (8-k)
September 10 2018 - 4:15PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
Current
Report
Pursuant
to Section 13 or 15(d) of
the
Securities Exchange Act of 1934
Date
of Report (Date of earliest event reported): September 4, 2018
RESPIRERX
PHARMACEUTICALS INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
1-16467
|
|
33-0303583
|
(State
or other jurisdiction
of
incorporation)
|
|
(Commission
File
Number)
|
|
(I.R.S
Employer
Identification
No.)
|
|
|
|
126
Valley Road, Suite C
Glen
Rock, New Jersey
|
|
07452
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (201) 444-4947
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
[ ]
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
[ ]
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
[ ]
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities act of 1933 (§230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging
growth company [ ]
If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [ ]
Item
1.01. Entry into a Material Definitive Agreement
On
September 4, 2018 (the “Effective Date”), RespireRx Pharmaceuticals Inc. (the “Company”) entered into
a Development and Supply Agreement (the “Agreement”) with Noramco, Inc. (“Noramco”), by which Noramco
agreed to (i) provide all of the active pharmaceutical ingredient (“API”) estimated to be needed for the clinical
development process for both the first- and second-generation products (each a “Product” and collectively, the “Products”),
three validation batches for NDA filing(s) and adequate supply for the initial inventory stocking for the wholesale and retail
channels, subject to certain limitations, (ii) maintain or file valid drug master files (“DMFs”) with the Food and
Drug Administration (“FDA”) or any other regulatory authority and provide the Company with access or a right of reference
letter entitling the Company to make continuing reference to the DMFs during the term of the agreement in connection with any
regulatory filings made with the FDA by the Company, (iii) participate on a development committee, and (iv) make available its
regulatory consultants, collaborate with any regulatory consulting firms engaged by the Company, and participate in all FDA or
Drug Enforcement Agency meetings as appropriate and as related to the API.
In
consideration for these supplies and services, the Company (i) agreed to purchase exclusively from Noramco during the commercialization
phase all API for its Products at a pre-determined price subject to certain producer price adjustments, and (ii) agreed to Noramco’s
participation in the economic success of the commercialized Product or Products up to the earlier of the achievement of a maximum
dollar amount or the expiration of a period of time. The Agreement will expire five years after the commercialization of the Products
unless sooner terminated by the terms of the Agreement. The Agreement includes customary termination, indemnification, confidentiality,
intellectual property and other provisions.
The
foregoing description of the Agreement does not purport to be complete and is qualified in its entirety by the Agreement, a copy
of which the Company intends to file as an exhibit to the Company’s Form 10-Q for the quarterly period ending September
30, 2018, with portions omitted and separately filed with the Securities and Exchange Commission pursuant to a request for confidential
treatment.
Item
8.01. Other Events
On
September 10, 2018, the Company issued a press release announcing its entry into the Agreement. A copy of the press release is
furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item
9.01. Financial Statements and Exhibits
(d)
Exhibits.
A
list of exhibits required to be filed as part of this report is set forth in the Exhibit Index, which is presented elsewhere in
this document, and is incorporated herein by reference.
EXHIBIT
INDEX
*
Furnished herewith.
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
Date:
September 10, 2018
|
RESPIRERX
PHARMACEUTICALS INC.
|
|
(Registrant)
|
|
|
|
|
By:
|
/s/
Jeff E. Margolis
|
|
|
Jeff
E. Margolis
|
|
|
SVP,
CFO, Secretary and Treasurer
|
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Mar 2024 to Apr 2024
RespireRx Pharmaceuticals (PK) (USOTC:RSPI)
Historical Stock Chart
From Apr 2023 to Apr 2024